Three months after the oral hearings were held at the European Court of Justice (ECJ), the Advocate General Yves Bot today published his opinion on the issue of third-party ownership in the case of the German branch of the Celesio subsidiary DocMorris (AZ C-171-07).
Drug delivery company pSivida Corp (NASDAQ:PSDV)(ASX:PVA) today announced that a clinical trial has begun using its MedidurTM delivery technology to treat a form of dry-Age related Macular Degeneration (dry-AMD).
Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) recently announced the Company's most important commercial milestone to date with the signing of a full license agreement with SSL International for the development of the VivaGel(R)-coated condom. SSL manufactures and markets Durex(R), the world's number one condom.
Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX:BLT)(PINK:BNIKF) announced today that Dr Amrita Krishnan, had presented a poster on the human HIV trial at the American Society of Hematology conference held in San Francisco CA USA.
Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) today announced new data showing that SPL7013, the active ingredient in its topical microbicide VivaGel(R), inhibits all four strains of the human papillomavirus (HPV) targeted by the two marketed cervical cancer vaccines.
After hearing the words, "you've got cancer," most patients are given a drug or combination of agents according to guidelines or standards of care. These treatments, in the oncologist's best judgment, are considered most likely to work based on the results of clinical studies in patients with similar tumor types. Cancer patients often require several courses of drugs and regimens sequentially, that are ineffective or poorly tolerated, prior to identifying the optimal therapy.
Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) announced today the appointment of Mr Richard Hill as a non executive Director.
